Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

Coverage, in order

1. 7h ago
   
   MedPage Today indie

   Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

   (MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.